LEO Pharma and ICON have announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective. The mission of the partnership is to improve the lives of dermatology patients with access to innovative clinical trials and the launch of new medicines.
The partnership will leverage both fully outsourced and functional outsourcing models in a hybrid approach. In supporting LEO Pharma through this partnership, ICON will draw upon a team from across its business to deliver tailored solutions, bringing capabilities including its laboratories, Accellacare site-network, FIRECREST site management, and DCT capabilities.
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology. (2023, March 10). Business Wire.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.